Navigation Links
OncoGenex Reports Third Quarter 2009 Financial Results
Date:11/5/2009

l in patients with solid tumors; - continuing an investigator-sponsored Phase 1 clinical trial evaluating OGX-427 treatment in patients with bladder cancer; - continuing critical path initiatives including manufacturing and clinical trial readiness activities in anticipation of OGX-011 Phase 3 clinical trials; and - meeting working capital needs, capital expenditures and general corporate purposes.

"We have continued to make solid progress in advancing our product pipeline, most recently with the receipt of Fast Track Designation from the U.S. Food & Drug Administration (FDA) for OGX-011 in combination with first-line docetaxel treatment and the initiation of a Phase 1 clinical trial evaluating OGX-427 in patients with bladder cancer," said Scott Cormack, President and CEO of OncoGenex. "We were also able to complete a $9.5 million registered direct offering that, in addition to strengthening our balance sheet and extending our runway, has given us leverage in our effort to secure a development and commercialization partnership for our OGX-011 program and enabled us to commence critical path initiatives including manufacturing and clinical trial readiness activities in anticipation of OGX-011 Phase 3 clinical trials."

"The partnering discussions continue to advance," Cormack added. "In addition to evaluating economic terms, we have been focusing on the level of commitment by potential partners to a development plan for OGX-011. As we are presently drafting definitive agreements, we believe that we are on track to secure a development and commercialization partnership for OGX-011."

It has been widely reported that the Galleon Group is in the process of liquidating all of its funds and winding down its operations. The Galleon Group has verbally confirmed to OncoGenex management that it completed the liquidation of its entire position in OncoGenex on October 20, 2009.


'/>"/>
SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
2. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
3. OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference
4. OncoGenex increases economic interest in lead cancer drug OGX-011
5. OncoGenex receives completed Special Protocol Assessment for primary registration study of lead drug candidate OGX-011
6. Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
7. FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals Lead Product Candidate OGX-011
8. OncoGenex Pharmaceuticals announces out-license of TOCOSOL Paclitaxel to Eagle Pharmaceuticals
9. OncoGenex To Present At The BioContact Quebec 2008 Annual Conference
10. OncoGenex Achieves Key Regulatory Milestone for Lead Product Candidate, OGX-011
11. OncoGenex Pharmaceuticals to Release Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... Research and Markets ( http://www.researchandmarkets.com/research/rcv4lq/gene_therapy ) ... Market, 2015 - 2025" report to their offering. ... provides an extensive study on the marketed and pipeline ... out in this field for over a decade but ... Asian markets; one approved in the EU). There are ...
(Date:3/3/2015)... BlueInGreen announces the ... sales network. The business venture will bring the ... Atlantic Provinces, exclusively through Resource Systems. , Since ... Canada’s premiere manufacturing representative firms, hosting a diverse ... and wastewater markets. More information on Resource Systems ...
(Date:3/3/2015)... The winners of awards for supply chain ... Global Supply Chain Resiliency Council (GSCRC) at ... February 25th, 2015, at the Hyatt Regency in Santa ... together supply chain risk management and resiliency practitioners with ... through opportunities to collaborate, develop and share best practices, ...
(Date:3/3/2015)... , March 3, 2015  Rosa & Co. LLC, ... modeling and simulation research, today announced it has two ... Society for Clinical Pharmacology and Therapeutics meeting in ...   Logo - http://photos.prnewswire.com/prnh/20150302/179058LOGO   ... present a poster describing a quantitative systems pharmacology approach ...
Breaking Biology Technology:Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 2Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 3Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 4Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 5Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 6Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 7BlueInGreen® Continues Canadian Expansion, Partners with Resource Systems Inc. 2Global Supply Chain Resiliency Council Names Award Winners 2Global Supply Chain Resiliency Council Names Award Winners 3Global Supply Chain Resiliency Council Names Award Winners 4Rosa & Co. Announces Two Poster Presentations at the American Society for Clinical Pharmacology and Therapeutics 2015 Annual Meeting 2Rosa & Co. Announces Two Poster Presentations at the American Society for Clinical Pharmacology and Therapeutics 2015 Annual Meeting 3
... a way to wake up the immune system to ... a nanoscale container called a vault directly into lung ... disease growth. The vaults, barrel-shaped nanoscale capsules found ... to slowly release a protein, the chemokine CCL21, into ...
... physical therapists are delighted the members of the California ... importance of Senate Bill 924 and its value to ... Physical Therapy Association, will improve the health care process ... delays and unnecessary costs because they have been unable ...
... Calif., May 3, 2011 Sangamo BioSciences, Inc. (Nasdaq: ... and CEO, will provide an update on the progress of ... company,s business strategy at two investor conferences in the month ... Lynch Health Care Conference at 10:40 am PT (1:40 pm ...
Cached Biology Technology:UCLA scientists discover new way to wake up the immune system using nano vaults to deliver drugs 2UCLA scientists discover new way to wake up the immune system using nano vaults to deliver drugs 3UCLA scientists discover new way to wake up the immune system using nano vaults to deliver drugs 4Sangamo BioSciences Announces Presentation at Two Upcoming Investor Conferences 2
(Date:2/18/2015)... , Feb. 18, 2015  Cepheid (NASDAQ: CPHD ... the following conferences, and invited investors to participate via webcast. ... Boston, MA Tuesday, March 3, 2015 at 11.20 ... Orlando, FL Wednesday, March 4, 2015 ... To access the live webcasts for these events, please visit ...
(Date:2/11/2015)... According to a ... Product (Cards and Readers, Biometrics, Controllers, Management Software), ... Healthcare, Education) and By Geography - Global Forecast and Analysis to ... Control Market is expected to reach $10.4 ... of 10.6% between 2014 and 2020. ...
(Date:2/5/2015)... Feb. 5, 2015  Marken is starting its 35 ... has launched a new marketing campaign to solidify its ... The new campaign focuses on First as ... shipments. The first headline in the series, ... priorities with its client,s priorities. Marken recognizes the need ...
Breaking Biology News(10 mins):Cepheid to Webcast Upcoming Financial Presentations 2Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4Marken Launches New Patient-Centric Campaign 2
... dangers to human health and the environment. North Carolina ... from the U.S. Environmental Protection Agency (EPA) that targets ... overflows every year, and will give urban planners new ... At issue are overflows from "sanitary" sewer systems, ...
... scientists have inventoried an astonishing abundance, diversity and distribution of ... that somehow manage a living in a frigid black world ... Revealed via deep-towed cameras, sonar and other vanguard ... now number 17,650, a diverse collection of species ranging from ...
... b3c newswire / - KINAXO Biotechnologies GmbH ... two new investors in the company, Leifina and Conmit ... Schumacher has been elected as a new member of ... Ullrich, Hellmut Kirchner, Manfred Ferber as well as the ...
Cached Biology News:Lose the fat: Targeting grease to curtail sewer overflows 2Beyond sunlight: Explorers census 17,650 ocean species between edge of darkness and black abyss 2Beyond sunlight: Explorers census 17,650 ocean species between edge of darkness and black abyss 3Beyond sunlight: Explorers census 17,650 ocean species between edge of darkness and black abyss 4Beyond sunlight: Explorers census 17,650 ocean species between edge of darkness and black abyss 5Beyond sunlight: Explorers census 17,650 ocean species between edge of darkness and black abyss 6Beyond sunlight: Explorers census 17,650 ocean species between edge of darkness and black abyss 7Beyond sunlight: Explorers census 17,650 ocean species between edge of darkness and black abyss 8Beyond sunlight: Explorers census 17,650 ocean species between edge of darkness and black abyss 9KINAXO Completes Financing Round to Enhance Biomarker Development 2KINAXO Completes Financing Round to Enhance Biomarker Development 3
BD Falcon 850 cm Smooth-surface TufRol Roller Bottle, tissue-culture treated polystyrene, blow-molded one-piece design, with easy on/off non-vented cap. (2/sp, 20/ca) Packaging: 2 / pack, 20 /...
... Protein Kit is a simple and convenient method ... The kit has been optimized for use with ... used for any fungus species that is susceptible ... procedure effectively generates spheroplasts of yeast cells that ...
... syringe pump series combines Harvard Apparatuss best pump ... a wide range of configuration options. A lookup ... of syringes from all the major manufacturers. A ... the pertinent information from across the lab. All ...
... PHD2000 syringe pump series combines Harvard Apparatuss best ... and a wide range of configuration options. A ... dimensions of syringes from all the major manufacturers. ... all the pertinent information from across the lab. ...
Biology Products: